Overview
- Neonatal hypoglycaemia is one of the most common metabolic emergencies in the newborn period and a critical component of the NETS stabilisation bundle.
- It requires systematic identification and correction before and during transport, as unrecognised or inadequately treated hypoglycaemia risks acute neuronal injury and long-term neurodevelopmental sequelae.
- The transport environment introduces additional physiological stressors, thermal instability, vibration, motion, noise, and limited investigative access, that amplify both the risk and the management challenge.
Epidemiology and Aetiology
Incidence
- Neonatal hypoglycaemia occurs in approximately 5-15% of all neonates; rates are substantially higher in recognised at-risk groups.
- Symptomatic or injurious hypoglycaemia is less common but clinically critical.
At-Risk Groups
| Risk Category | Mechanism | Examples |
|---|---|---|
| Hyperinsulinism | Excess insulin suppresses hepatic glucose output and promotes peripheral uptake | IDM, LGA, Beckwith-Wiedemann syndrome, congenital hyperinsulinism |
| Reduced substrate stores | Inadequate glycogen and fat reserves | Prematurity (<37 weeks), IUGR/SGA |
| Increased glucose utilisation | Stress states raise metabolic demand | Perinatal asphyxia, sepsis, hypothermia, respiratory distress |
| Counter-regulatory hormone deficiency | Impaired glycogenolysis/gluconeogenesis | Hypopituitarism, adrenal insufficiency, glucagon deficiency |
| Inborn errors of metabolism | Impaired alternative fuel mobilisation | Fatty acid oxidation disorders, glycogen storage diseases |
| Iatrogenic | Abrupt cessation of dextrose infusion; transplacental drug effect | Maternal beta-blockers, oral hypoglycaemics |
Pathophysiology
- At birth the continuous transplacental glucose supply is abruptly interrupted.
- In a healthy term neonate, blood glucose falls transiently over the first 1-2 hours then stabilises as glycogenolysis, gluconeogenesis, and fatty acid oxidation activate.
- Ketone bodies and lactate serve as alternative neuronal fuels.
Failure of counter-regulatory responses, due to substrate deficiency, inappropriate hyperinsulinism, or hormonal insufficiency, results in hypoglycaemia. The neonatal brain is particularly vulnerable because:
- Glucose utilisation rate is high relative to body weight
- Hepatic glycogen stores are exhausted rapidly (within 8-12 hours in preterm infants)
- Counter-regulatory hormone responses (glucagon, cortisol, growth hormone, catecholamines) may be immature or deficient
Prolonged or profound hypoglycaemia causes neuronal energy failure, excitotoxic injury, and cerebral oedema, with characteristic vulnerability of the occipital cortex (explaining the posterior-predominant MRI injury pattern seen in persistent neonatal hypoglycaemia).
Clinical Features
Symptoms and Signs
- Hypoglycaemia may be asymptomatic (detected on routine screening) or symptomatic.
- The distinction matters for management urgency.
| Category | Features |
|---|---|
| Neurological excitatory | Jitteriness, tremors, irritability, high-pitched cry |
| Neurological depressive | Lethargy, hypotonia, poor feeding, apathy |
| Autonomic | Pallor, sweating, tachycardia |
| Severe / neuroglycopenic | Apnoea, seizures, coma, cardiovascular instability |
Key point: Many neonates with documented hypoglycaemia are asymptomatic. Absence of symptoms does not exclude significant or injurious hypoglycaemia in at-risk groups.
Investigations
Screening
- Point-of-care blood glucose (POC-BGL) using a bedside glucometer is the primary screening tool.
- Because all glucometers carry documented error ranges, any reading at or near the treatment threshold must be confirmed with a laboratory plasma glucose (gold standard).
Threshold Definitions
There is international variation in threshold definitions. Thresholds consistent with Australian/NZ NETS and RCH clinical practice guidelines:
| Postnatal Age | Action Threshold |
|---|---|
| First 4 hours | <2.0 mmol/L (symptomatic: treat immediately regardless of value) |
| 4-24 hours | <2.6 mmol/L |
| After 24 hours | <2.8 mmol/L |
Persistent or recurrent hypoglycaemia below 2.8 mmol/L after 48 hours warrants investigation for an underlying cause.
Critical Sample (Collected at the Time of Hypoglycaemia)
Ideally collected before treatment if clinically safe; should not delay urgent correction.
| Sample | Purpose |
|---|---|
| Plasma glucose (laboratory) | Confirm hypoglycaemia |
| Insulin | Hyperinsulinism (inappropriately elevated if >2 mU/L during documented hypoglycaemia) |
| C-peptide | Endogenous insulin production |
| Cortisol | Adrenal insufficiency |
| Growth hormone | Hypopituitarism |
| Glucagon | Glucagon deficiency |
| Free fatty acids + beta-hydroxybutyrate | Low FFA + low ketones = hyperinsulinism; fatty acid oxidation disorders |
| Lactate, ammonia | Metabolic disorders |
| Acylcarnitine profile (dried blood spot) | Fatty acid oxidation disorders |
| Urine organic acids | Organic acidaemias |
Diagnosis
Neonatal hypoglycaemia is defined biochemically; clinical context determines the threshold for intervention.
- Operational threshold: BGL at which intervention is warranted based on risk of neuronal injury, irrespective of symptoms, typically <2.6 mmol/L in at-risk neonates
- Symptomatic hypoglycaemia: Any glucose level with compatible clinical features, treat immediately regardless of absolute value
- Persistent hypoglycaemia: More than three episodes, or glucose infusion rate (GIR) >8 mg/kg/min required to maintain euglycaemia, mandates investigation for hyperinsulinism or endocrine/metabolic aetiology
GIR Calculation
$$\text{GIR (mg/kg/min)} = \frac{\text{Dextrose concentration (\%)} \times \text{rate (mL/hr)}}{6 \times \text{weight (kg)}}$$
GIR >8 mg/kg/min suggests hyperinsulinism; GIR >12-15 mg/kg/min is strongly suggestive.
Management
General Principles
- Restore and maintain euglycaemia (target plasma glucose ≥2.8 mmol/L; ≥3.0 mmol/L in symptomatic or high-risk infants)
- Prevent neuroglycopenic injury
- Identify and treat the underlying cause
- Support enteral feeds as the preferred long-term strategy
Asymptomatic At-Risk Neonates
- Screen before feeds at defined intervals
- Encourage early, frequent breastfeeding (within 30 minutes of birth)
- Supplemental feeds (expressed breast milk or formula) if BGL remains <2.6 mmol/L despite feeding
- IV dextrose if unable to tolerate enteral feeds or BGL does not respond
Symptomatic or Severe Hypoglycaemia (BGL <2.0 mmol/L)
- IV dextrose bolus: 10% dextrose 2 mL/kg IV over 5 minutes (delivers ~200 mg/kg glucose)
- Follow immediately with continuous IV dextrose infusion at GIR 4-6 mg/kg/min
- Recheck BGL 15-30 minutes after bolus
- Avoid 50% dextrose in neonates, hyperosmolarity and vascular injury
- Peripheral IV: maximum dextrose concentration 12.5%; higher concentrations require a central line (UVC or PICC)
Escalation
| GIR Required | Action |
|---|---|
| 4-6 mg/kg/min | Standard starting infusion |
| 6-8 mg/kg/min | Increase concentration or rate; consider central line |
| 8-12 mg/kg/min | Suspect hyperinsulinism; collect critical samples; specialist input |
| >12 mg/kg/min | Pharmacological therapy (see below) |
Pharmacological Options (Specialist-Directed)
| Drug | Indication | Notes |
|---|---|---|
| Glucagon | Acute hyperinsulinism | IM/IV bolus then infusion; ineffective in substrate-depleted states (SGA, preterm) |
| Diazoxide | Persistent hyperinsulinism | Oral/IV; first-line; inhibits pancreatic beta-cell insulin secretion |
| Hydrocortisone | Refractory hypoglycaemia, suspected adrenal insufficiency | Promotes gluconeogenesis; antagonises insulin action |
| Octreotide | Diazoxide-unresponsive hyperinsulinism | Somatostatin analogue |
Management During Neonatal Retrieval and Transport (NETS Stabilisation Bundle)
- The NETS pre-transport stabilisation bundle requires systematic assessment and optimisation across respiratory, cardiovascular, metabolic, neurological, thermoregulatory, septic, haematological, and fluid parameters.
- Glucose management is a central metabolic pillar.
- The aim is to optimise the infant's condition in advance of transport, not merely to maintain the status quo.
Pre-Transport Stabilisation
Before the retrieval team departs the referring unit:
- Screen and document blood glucose in all at-risk neonates
- Establish IV access (peripheral IV first; UVC if peripheral access fails)
- Commence IV dextrose infusion and achieve stable BGL ≥2.8 mmol/L
- Document current GIR and dextrose concentration
- Do not initiate a dextrose bolus immediately before handover without a subsequent infusion running
- Collect critical samples at the time of hypoglycaemia if persistent/unexplained
Principle: A neonate should not be transported with an unstable or falling BGL, metabolic stability is as essential as thermal and respiratory stability before departure. Transfer should not proceed unless the central temperature is ≥36.5°C; the same logic applies to glucose.
During Transport: Challenges and Mitigations
| Challenge | Mitigation |
|---|---|
| Limited venous access | Establish UVC or reliable peripheral IV prior to departure; carry additional IV supplies |
| Interrupted enteral feeds | Maintain IV dextrose throughout transport |
| Hypothermia increasing glucose demand | Pre-warm transport incubator; use phase-change gel mattress; apply hat and plastic wrap (VLBW); use warmed, humidified ventilator gases |
| Restricted POC testing in transit | Check BGL at departure; aim for at least one check during journeys >1 hour |
| Syringe pump failure or power loss | Carry a backup pump; all equipment must be independently battery-powered and secured in the vehicle |
| Limited access to infant in transit | Pre-calculate and set infusion rates before departure; minimise need for mid-transport changes; stop ambulance at first safe opportunity if intervention is needed |
| Vibration artefact on monitoring | Maintain unrestricted visual access to infant to assess colour, chest movement, and perfusion |
Temperature-Glucose Interaction
- Hypothermia substantially increases glucose consumption by driving non-shivering thermogenesis and raising metabolic rate; it also impairs surfactant production and renders metabolic processes less efficient.
- A neonate in the thermoneutral zone requires less glucose and is more stable during transport.
Measures to reduce thermal stress include:
- Pre-warming the transport incubator and the ambulance
- Phase-change (acetate) gel mattress under the infant
- Hat; plastic wrap or occlusive dressing for VLBW infants
- Incubator portholes to minimise exposure during procedures
- Warmed, humidified ventilator gases
- Continuous temperature monitoring throughout
A cold neonate arriving at the NICU with hypoglycaemia may have had adequate glucose support that was overwhelmed by thermal stress during transport.
Respiratory Support and Glucose During Transport
- Neonates requiring CPAP or mechanical ventilation are at high risk of hypoglycaemia (particularly preterm infants and those with sepsis).
- Infants on CPAP during transport cannot feed enterally; IV glucose must be maintained.
- All VLBW neonates who required intubation for resuscitation should be transported with ventilator support in the transport incubator.
- The decision to extubate to nCPAP prior to transport versus remaining intubated is made by the retrieval team based on the infant's stability; both are acceptable practices and assessment can continue on arrival at the NICU.
- Continuous end-tidal CO₂ (EtCO₂) monitoring is recommended during ventilated transport to rapidly identify ventilation failure from endotracheal tube displacement or blockage.
- Sidestream sampling adds negligible dead space; the qualitative waveform is more useful than the absolute value in this setting.
Complications
| Complication | Notes |
|---|---|
| Acute neuronal injury | Seizures, encephalopathy, risk increases with duration and depth of hypoglycaemia |
| Occipital cortex injury | Characteristic posterior-predominant MRI injury pattern with persistent hypoglycaemia |
| Cerebral visual impairment | Sequela of posterior cortical injury |
| Intellectual disability / developmental delay | Long-term consequence of severe or recurrent hypoglycaemia |
| Iatrogenic hyperglycaemia | Excessive dextrose → osmotic diuresis; increased IVH risk in preterm neonates |
| Hyponatraemia | Hypotonic solutions or excessive free water |
| Vascular injury | Dextrose >12.5% via peripheral IV → phlebitis, extravasation, tissue necrosis |
Prognosis and Follow-Up
Prognosis depends on:
- Severity and duration: Brief, isolated episodes in healthy term infants carry an excellent prognosis
- Aetiology: Hyperinsulinism and persistent hypoglycaemia carry higher neurodevelopmental risk than transient hypoglycaemia in IDM
- Timeliness of treatment: Prompt recognition and correction significantly improves outcomes
- Associated conditions: HIE, prematurity, and sepsis worsen outcomes independently
Infants with recurrent symptomatic hypoglycaemia, documented seizures, or MRI evidence of injury require:
- Neurodevelopmental surveillance (e.g. Bayley Scales at 12-24 months corrected age)
- Visual assessment (posterior cortical injury → cerebral visual impairment)
- Ophthalmology review
- Follow-up with metabolic/endocrine service if a persistent cause is identified
Indications for NICU Admission and Retrieval
| Situation | Action |
|---|---|
| Symptomatic hypoglycaemia in any neonate | Immediate IV treatment; NICU/SCN admission |
| BGL persistently <2.6 mmol/L despite enteral feeds | IV dextrose; SCN/NICU admission |
| GIR requirement >8 mg/kg/min | Retrieve to tertiary NICU; collect critical samples; endocrine/metabolic input |
| Hypoglycaemia with seizures | Emergency treatment; NICU retrieval; EEG; MRI when stable |
| Suspected hyperinsulinism (LGA, IDM, Beckwith-Wiedemann) | Admission for monitoring; endocrine review |
| SGA/IUGR with recurrent hypoglycaemia | NICU admission; screen for endocrine and metabolic aetiology |
| Hypoglycaemia in the context of sepsis or perinatal asphyxia | Treat primary illness and hypoglycaemia concurrently; NICU care |
- All neonates requiring retrieval for hypoglycaemia must have IV access established and a running dextrose infusion documented before the transport team departs the referring hospital.
- Communication with the transport coordinator (NSW NETS, PIPER VIC, Medi-Retrieval QLD, or equivalent state service) must include the current BGL, GIR, dextrose concentration, and any critical samples collected.